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Contributes to Elevated Triglycerides
and Severity of CAD by Interfering
With MicroRNA 3201 Binding Efﬁciency
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MaBACKGROUND Recent genome-wide association studies identiﬁed the APOA5/A4/C3/A1 gene cluster polymorphisms
inﬂuencing triglyceride level and risk of coronary artery disease (CAD).
OBJECTIVES The purposes of this study were to ﬁne-map triglyceride association signals in the APOA5/A4/C3/A1 gene
cluster and then explore the clinical relevance in CAD and potential underlying mechanisms.
METHODS We resequenced the APOA5/A4/C3/A1 gene cluster in 200 patients with extremely high triglyceride levels
($10 mm/l) and 200 healthy control subjects who were ethnically matched and genotyped 20 genetic markers among
4,991 participants with Chinese Han ethnicity. Subsequently, 8 risk markers were investigated in 917 early-onset and
1,149 late-onset CAD patients, respectively. The molecular mechanism was explored.
RESULTS By resequencing, a number of newly and potentially functional variants were identiﬁed, and both the common
and rare variants have remarkable cumulative effects on hypertriglyceridemia risk. Of note, gene dosage of rs2266788
demonstrated a robust association with triglyceride level (p ¼ 1.39  1019), modiﬁed Gensini scores (p ¼ 1.67  103),
and numbers of vascular lesions in CAD patients (odds ratio: 1.96, 95% conﬁdence interval: 1.31 to 2.14, p ¼ 8.96 
104). Functional study demonstrated that the rs2266788 C allele destroyed microRNA 3201 binding to the 30 UTR of
APOA5, resulting in prolonging the half-life of APOA5 messenger RNA and increasing its expression levels.
CONCLUSIONS Genetic variants in APOA5/A4/C3/A1 gene cluster play an important role in the regulation of plasma
triglyceride levels by an increased APOA5 concentration and contribute to the severity of CAD. (J Am Coll Cardiol 2014;
64:267–77) © 2014 by the American College of Cardiology Foundation. Open access under CC BY-NC-ND license.H ypertriglyceridemia (HTG), a deﬁningcomponent of the metabolic syndrome (1),is associated with numerous comorbidities,
including increased cardiovascular morbidity and
mortality risk (2). Recently, a number of genome-
wide association studies (GWAS) have successfully
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ABBR EV I A T I ON S
AND ACRONYMS
CAD = coronary artery disease
GWAS = genome-wide
association study(ies)
HDL-C = high-density
lipoprotein cholesterol
HTG = hypertriglyceridemia
LD = linkage disequilibrium
LDL-C = low-density
lipoprotein cholesterol
miR-3201 = microRNA 3201
mRNA = messenger RNA
SNP = single nucleotide
polymorphism
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268to contribute 38% of the genetic variance of
triglycerides, as well as explaining 11% of
high-density lipoprotein-cholesterol (HDL-C),
4% of low-density lipoprotein (LDL-C),
and 10% of apolipoprotein B genetic variance
(8). Increasing evidence has shown that high
triglyceride levels and single nucleotide
polymorphisms (SNPs) in the APOA5/A4/C3/
A1 gene cluster are associated with several
risk factors that substantially increase the
risk of coronary artery disease (CAD) (9–12).
Indeed, a large-scale meta-analysis involving
86,995 individuals of European descent
gives reliable evidence that this APOA5/
A4/C3/A1 gene cluster is implicated in theSEE PAGE 278pathogenesis of CAD (12). In addition, prospective
epidemiological and triglyceride-mediated pathway
studies also have found the positive association
between circulating triglyceride concentration and
the risk of CAD (10,13,14). Despite the evidence, the
extent to which triglycerides directly promote car-
diovascular disease or represents a biomarker of risk
has been debated for 3 decades (15). Other remaining
questions are whether and how additional forms of
genetic variations, such as rare variants with large
individual effects, could contribute to the heritability
of a high plasma triglyceride status and whether
the APOA5/A4/C3/A1 gene cluster is related to the
severity of CAD, speciﬁcally in the Chinese Han
population. Thus, to ﬁne-map the actual susceptibility
variants, we resequenced all the exons of the APOA5/
A4/C3/A1 gene cluster in a total of 400 Chinese Han
participants: 200 patients with an extremely high
plasma triglyceride level ($10 mmol/l) and another
200 healthy control subjects. We also conducted a
comprehensive survey of 20 common SNPs for associ-
ations with triglyceride levels in an independent
Chinese Han cohort and investigated the molecular
mechanism for the SNP to contribute to a high triglyc-
eride level. Finally, we tested the hypothesis that
gene dosage of a risk allele in the APOA5/A4/C3/A1
gene cluster predicts CAD severity, which was angio-
graphically documented and stratiﬁed by the degree
of vascular lesions.
METHODS
STUDY DES I GN AND EL I G I B I L I T Y. Details on
sample recruitment, inclusion criteria, data collection,
and deﬁnition of risk factors are provided in the
expanded Methods section in the Online Appendix.
The clinical characteristics of the samples are shown inTable 1. In brief, the resequencing effort was con-
ducted in 200 affected individuals and 200 controls of
Chinese Han descent. Individuals with HTG were un-
related subjects with a diagnosis of Fredrickson HTG
phenotypes (16), deﬁned as having a fasting plasma
triglyceride level >10 mmol/l, from a the Department
of Clinical Chemistry, Tongji Hospital. Ethnically
and geographically matched control subjects were
recruited from individuals undergoing routine health
examinations at the Tongji Hospital in Wuhan, Hubei
Province. We chose controls with a maximal recorded
fasting plasma triglyceride levels <2.3 mmol/l to
exclude undiagnosed HTG (13). A total of 4,991
healthy, community-based Chinese Han individuals
were originally recruited from the general population
in 2004, with ages ranging from 20 to 85 years. At
baseline, a detailed demographic and family history of
all study participants was obtained via standardized
questionnaires. None of the individuals were using
lipid-lowering medication when the blood sample was
taken. In fasting venous blood samples, we measured
total cholesterol, HDL-C, triglycerides, and LDL-C
on the Roche modular DPP system (Roche, Basel,
Switzerland), according to standard procedures. The
distribution of serum TG levels for control subjects
and HTG patients are shown in Online Figure 1. The
CAD cohort, including 917 early-onset patients and
1,149 late-onset patients, were enrolled simulta-
neously from hospitalized patients in the Tongji
Hospital and the Institute of Hypertension (Wuhan,
China) between May 2004 and October 2011. The 222
angiographic cases with <20% stenosis in any coro-
nary artery were recruited and called 0-vessel disease
including 106 early-onset patients and 116 late-onset
patients. The modiﬁed Gensini scores and the num-
ber of lesions were previously reported (17,18). All
patients and control subjects were carefully matched
by geographic region of recruitment, were of Han
Chinese ancestry, and provided written informed
consent. This study was approved by the institutional
ethics committees of the local participating hospitals.
GENET I C VAR I AT ION SCREEN ING . Sequence
data of the APOA5/A4/C3/A1 gene cluster were
generated by Sanger sequencing, whereas 3 other
triglyceride-modulating genes (APOB, GCKR, LPL)
were screened by Ion Torrent semiconductor se-
quencing (Life Technologies, Carlsbad, California).
Details regarding primers, resequencing procedures,
and data analysis are given in Online Table 1 and the
Methods section in the Online Appendix.
TAGGING SNP SELECTION AND GENOTYPING.
A total of 20 SNPs within the APOA5/A4/C3/A1 gene
cluster were genotyped in our study. These SNPs
TABLE 1 Baseline Characteristics of the Study Sample
Cohort
HTG Sequencing
Cohort Cases
(n ¼ 200)
Control Sequencing
Cohort Cases
(n ¼ 200)
General Population
(n ¼ 4,991)
CAD Study
Early-Onset
CAD Cases
(n ¼ 917)
Late-Onset
CAD Cases
(n ¼ 1,149)
Age, yrs 47.98  11.37 45.8  7.79 49.77  14.45 50.36  7.31 66.46.96
Male, % 62.0 50.5 48.53 56.16 81.8
BMI, kg/m2 26.06  3.17 22.13  2.54 23.88  3.55 25.08  4.63 24.28  3.79
TC, mmol/l 7.51  7.63 4.11  0.97 4.39  1.08 4.55  1.24 4.35  2.40
HDL-C, mmol/l* 0.84  0.41 1.63  0.35 1.31  0.39 1.09  0.49 1.07  0.50
LDL-C, mmol/l* 1.93  3.34 2.24  0.77 2.47  0.89 2.61  0.96 2.46  1.04
TG, mmol/l* 18.62  1.83 0.54  0.10 1.54  1.27 2.34  6.43 1.95  4.63
Blood pressure, mm Hg
Systolic 118  14.27 116  14.69 118  16.36 133  21.69 141  15.16
Diastolic 77  9.4 78  7.2 75  11.24 82.95  13.87 80  12.38
Hypertension 0 0 711 (14.25) 467 (50.93) 763 (66.41)
Type 2 diabetes 0 0 176 (3.53) 135 (14.72) 187 (16.28)
Current/ex-smoker 0 0 1,487 (29.80) 378 (41.22) 606 (52.74)
Alcohol consumption, units/wk 0 0 277 (5.55) 82 (8.94) 87 (7.57)
Previous myocardial infarction 0 0 0 90 (9.8) 121 (10.5)
Heart failure 0 0 0 8 (0.87) 11 (0.96)
History of cerebrovascular disease 0 0 0 53 (5.78) 61 (5.31)
Coronary angiography
0-vessel disease — — — 95 (10.36) 107 (9.31)
1-vessel disease, — — — 290 (31.62) 299 (26.02)
2-vessel disease — — — 251 (27.37) 343 (29.85)
3-vessel disease — — — 283 (30.86) 400 (34.81)
Left main trunk disease — — — 745 (81.24) 937 (81.55)
Right coronary artery stenosis — — — 452 (49.29) 645 (56.14)
Values are mean  SD or n (%). *Lipid measurements were conducted after a 12-h fasting period.
BMI ¼ body mass index; CAD ¼ coronary artery disease; HDL-C ¼ high-density lipoprotein cholesterol; HTG ¼ hypertriglyceridemia; LDL-C ¼ low-density lipoprotein
cholesterol; TC ¼ total cholesterol; TG ¼ triglycerides.
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269cover a 150-kb genomic region on chromosome 11
(National Centre for Biotechnology Information build
GRCh37 from 116165000 to 116215000). TaqMan
50-nuclease assay on the TaqMan 7900HT Sequence
Detection System (Applied Biosystems, Foster City,
California) under standard conditions. Details re-
garding SNP selection as well as TaqMan perfor-
mances can be found in Online Table 2.
R I S K SCORE . The risk score was calculated on the
basis of 8 SNPs that were signiﬁcantly associated with
plasma triglyceride levels in the combined analysis.
We modeled the cumulative number of risk alleles
carried by each participant. For a detailed description
of the calculation methods, see the Methods section
in the Online Appendix.
FUNCT IONAL ANALY S I S . Bioinformatic analysis
shows that rs2266788 is located at microRNA 3201
(miR-3201) binding site of human APOA5 30 UTR, and
therefore we tested whether rs2266788*C destroyed
the miR-3201 binding site. Two 780-bp fragments
containing human APOA5 30 UTR rs2266788T andrs2266788C, respectively, were cloned into a p-MIR
vector downstream of luciferase reporter (Ambion,
Austin, Texas), and the resultant plasmids (p-MIR-T
and p-MIR-C) were transformed into 293T and HepG2
cells, respectively, with or without miR-3201 to
determine effects of the miR-3201 binding site by
detecting ﬂuorescence intensity according to the
manufacturer’s instructions.
Measurement of genotype-dependent plasma
levels of APOA5 was performed in 170 healthy par-
ticipants to investigate effects of different rs2266788
genotypes on APOA5 levels.
STAT I S T I CA L ANALY S I S . Statistical analyses
were performed with SPSS version 13.0 (SPSS, Inc.,
Chicago, Illinois) for Windows (Microsoft, Redmond,
Washington). Haploview version 4.1 (Informer Tech-
nologies, Inc.) was used to calculate linkage disequi-
librium (LD) and select tagging SNPs. Deviations
of genotype frequency from the Hardy-Weinberg
assumption were assessed using a chi-square test.
All biostatistics calculations were performed using
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270Prism (GraphPad Software, Inc., La Jolla, California).
All probability values were 2 sided, and p < 0.05
was considered signiﬁcant. Detailed descriptions
are available in Methods section in the Online
Appendix.
RESULTS
The triglyceride-modulating gene APOA5/A4/C3/A1
gene cluster, GCKR, LPL, and APOB were previously
reported (14,19). A total of 119 kb (including 20 kb
coding and 99 kb noncoding) were sequenced in 200
individuals with severe HTG and 200 control subjects
of Chinese Han descent. Cumulatively, we identiﬁed
171 DNA variants with an average of 1 variant per 695
bp of the reference human genome sequence
(Table 2). Of the variants, 60 were common poly-
morphisms (minor allele frequency >1%), whereas the
remaining 111 were rare variants, including 29 non-
coding, 17 synonymous, and 65 nonsynonymous
variants. Bioinformatics analysis suggests that 20 of
nonsynonymous variants are possibly or probably
damaging normal function of corresponding genes
(Online Table 3).
To test the hypothesis that these rare coding
variant (minor allele frequency <0.02) HTG-
associated genes are related to HTG disease cause,
we conducted rigorous analyses of these variants
found exclusively in either individuals with HTG or
control subjects, and the results revealed a signiﬁcantTABLE 2 Sequencing Summary
No. of genes 7
No. of exons 73
Genomic sequence covered, bp
Total 119,359
Coding 20,071
Noncoding 99,288
Total no. of variants 171
No. of rare variants
Total 111
Nonsynonymous 65
Synonymous 17
Noncoding 29
No. of common variants
Total 60
Nonsynonymous 23
Synonymous 8
Noncoding 29
No. of novel SNPs covered 72
No. of known dbSNPs covered 99
Values are n.
dbSNPs ¼ single-nucleotide polymorphism database; SNP ¼ single-nucleotide
polymorphism.accumulation of variants in the APOA5/A4/C3/A1 gene
cluster in affected individuals (p ¼ 2.0  104)
(Table 3), but not the other triglyceride-modulating
genes (p ¼ 0.225).
Given the signiﬁcant accumulation effect of rare
coding variants of the APOA5/A4/C3/A1 gene cluster,
we further genotyped and analyzed the effect of 20
common variants in a region of a 150-kb DNA
sequence of this gene cluster on triglyceride level in a
total of 4,991 participants. No deviation from the
Hardy-Weinberg equilibrium was observed for all
SNPs in these samples (p > 0.05). Ten of the 20 SNPs
within this region were statistically associated with
plasma triglyceride levels with Bonferroni correction
adjustment (correct p < 0.05) (see details in Online
Table 4). It is worth noting that 2 of these 10 SNPs,
rs2266788 and rs662799, were identiﬁed most signif-
icantly as being associated with plasma triglyceride
levels in the Chinese Han population after adjusting
for traditional risk factors (p ¼ 1.39  1019, p ¼ 4.74 
1036, respectively) (Fig. 1). For rs2266788 and
rs662799, the proportion of a 1-SD change in stan-
dardized log-transformed plasma triglyceride level
residual value for each copy of the risk allele was
0.131 and 0.178, respectively, and the contribution of
this genetic effect can explain 7.1% and 8.5%,
respectively, of the total variance of plasma triglyc-
eride levels in our population. We also found partial
polymorphisms in this gene cluster associated with
HDL-C, LDL-C, and total plasma cholesterol (Online
Table 5).
Given that 3 SNPs (rs2266788, rs662799, and
rs964184) were in a strong LD (D0 range, 0.96 to 1.0TABLE 3 Accumulation of Rare Coding Variants in Individuals
With HTG and Control Subjects
Exclusive Variants* HTG Control Subjects
APOA5 11 0
APOA4 6 0
APOC3 1 2
APOA1 1 0
Total 19 2
p Value 2.0  104
GCKR 6 3
LPL 3 2
APOB 20 15
Total 29 20
p Value 0.225
Values are numbers of variants. *Exclusive variants refer to novel variants found
exclusively in individuals with HTG or exclusively in healthy control subjects; the
Fisher exact test was used to calculate the signiﬁcance of accumulation effect in
individuals with HTG, with nominal statistical signiﬁcance deﬁned as a 2-sided
p value <0.05.
HTG ¼ hypertriglyceridemia.
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271[Online Fig. 2], based on the HapMap project Phase II
database), rs2266788 can capture rs964184 and
rs662799. Therefore, 8 risk SNPs (rs2266788 and the
remaining 7 risk SNPs) were selected for the risk score
analysis. We divided the general population into
tertiles by weighted allelic risk scores and found a
signiﬁcant association between the tertiles of accu-
mulative risk scores and gradually increased triglyc-
eride levels (p ¼ 1.34  108) (Fig. 2A) and a reverse
association with HDL-C (p ¼ 2.37  103) (Fig. 2B),
indicating that these SNPs have cumulative effect on
plasma triglyceride and HDL-C levels.
We further assessed the relationship between
these 8 risk SNPs and modiﬁed Gensini coronary
scores and found that these risk SNPs have a cumu-
lative association with the Gensini score (2.25 
103) (Fig. 2C). In addition, 2 SNPs (rs2266788 and
rs662799), which showed the greatest association
with plasma triglyceride levels, also are associated
with modiﬁed Gensini scores in combined analysis
after multiple corrections (p ¼ 0.003 and p ¼ 1.67 
103, respectively) (Fig. 2D).
Subsequently, we explored whether the gene
dosage of these 2 SNPs (rs2266788 and rs662799) is
associated with vascular lesions and contributed to
CAD severity as well. Results showed that the higher
gene dosage carriers of the rs2266788C had a signiﬁ-
cantly greater chance of having a 3-vessel coronary
lesion on combined analysis (Table 4) (p ¼ 8.96 
104, odds ratio: 1.96, 95% conﬁdence interval: 1.31 to
2.14). Similar results can be found in the early- and
late-onset studies. However, no signiﬁcant effect was
observed for the rs662799 variant after multiple
corrections.
As shown in Figure 3, CAD patients with the CC
genotype (meaning both copies of the gene contain
the C allele) of rs2266788 have a higher proportion of
right coronary artery stenosis (p ¼ 0.005, odds ratio:
1.77, 95% conﬁdence interval: 1.19 to 2.65) (Fig. 3A),
but has no effect on left main trunk disease (p ¼
0.316). With an increasing number of complex mani-
festations, the minor allele frequency of rs2266788
was signiﬁcantly and gradually higher (p ¼ 0.019)
(Fig. 3C).
FUNCT IONAL ANALY S I S O F R S 2 2 6 6 7 8 8 AND
RS6 6 2 7 9 9 . Previous reports have shown that
rs662799 had no effect on relative luciferase expres-
sion (20), and no transcriptional factors mapped to
this site (21). Given that rs2266788 was in strong
LD with rs662799 in the Han Chinese population
(r2 ¼ 0.92), maintaining important clinical relevance,
we focused on rs2266788, which is located in the 30
UTR of APOA5, for further functional analysis.Further bioinformatics analysis by a computer
alignment program demonstrated that the rs2266788
C allele, not the T allele, destroyed miR-3201 binding
to the 30 UTR of APOA5 (Fig. 4A). To test the prediction
model that the miR-3201 can functionally interact
with the 30 UTR of APOA5, 293T and HepG2 cells were
used for transfection of APOA5 30 UTR–based reporter
constructs (pMIR-T, with the T allele or pMIR-C, with
the C allele). As shown in Figures 4B and 4C, compared
with a negative control, luciferase activity decreased
with cotransfection of pMIR-T and miR-3201 in both
293T cells (25  1.21%, p ¼ 0.006) and HepG2 cells
(43  1.23%, p ¼ 0.01), respectively. On the contrary,
miR-3201 had no effect on ﬁreﬂy luciferase activity
when the pMIR-C construct destroying the predicted
miR-3201 binding sitewas transfected (Figs. 4B and 4C).
Furthermore, we performed messenger RNA (mRNA)
turnover experiments to monitor the inﬂuence of
rs2266788 on mRNA stability. The estimated half-life
of the rs2266788 T transcript was w2 h shorter than
the rs2266788 C construct (9.8  0.5 vs. 13.7  0.2,
p < 0.001) (Online Fig. 3).
We further explored the effects of miR-3201 on
APOA5 translation (e.g., protein expression in
cultured HepG2 cells in vitro), Western blot results
showed that overexpression miR-3201 downregulated
APOA5 expression level and the inhibition of miR-
3201 expression using its inhibitor signiﬁcantly
upregulated expression of APOA5 in HepG2 cells
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272(Fig. 4D). These results were consistent with the real-
time polymerase chain reaction data (Online Fig. 4).
To further conﬁrm the effects of miR-3201 and
its inhibitor on endogenous APOA5 expression, we
sequenced 9 of the human hepatoma cell lines
(including HepG2, HuH-7, Hep3B, LM3, HLE, HLF 97L,
PLC, L02, and so on), and, fortunately, the cell line
HLF was identiﬁed to be a heterozygous genotype (CT
type) (Online Fig. 5), and then we used this cell line to
perform experiments. Results showed that no signif-
icant effect of miR-3201 on APOA5 expression was
found in HLF cells (Online Fig. 6). Cotransfection
of pcMV6-ApoA5 and miR-3201 in HepG2 cells efﬁ-
ciently restored APOA5 expression with enhanced
expression of miR-3201 (Fig. 4E). In vivo, plasma
concentrations of APOA5 were higher in subjects withthe CC genotype (n ¼ 25) than in those with the CT
genotype (n ¼ 47, p ¼ 0.032) or the TT genotype
(n ¼ 98, p ¼ 0.038) (Fig. 4F). These results are also
consistent with the clinical and biochemical proﬁles
of the CC, CT, and TT genotype subgroups (Online
Table 6), suggesting that miR-3201 is truly causal
with higher triglyceride levels in subjects carrying the
C allele.
Taken together, these data indicate an interaction
between miR-3201 and a speciﬁc region of the 30 UTR
of APOA5 containing the T, but not the C allele, which
subsequently enhances degradation of its mRNA and
reduces the protein expression level.
DISCUSSION
This population-based study on APOA5/A4/C3/A1
gene cluster variations provides clear evidence
of associations with the development of HTG
(Central Illustration). Based on our large-scale genetic
ﬁne-mapping effort for the APOA5/A4/C3/A1 gene
cluster, a large number of common polymorphisms
and rare mutations were identiﬁed, and some of the
rare variants are reported for the ﬁrst time in the
Chinese Han population. These common and rare
variants have remarkable cumulative effects on HTG
risk, and these results contribute to the unexplained
genetic component of HTG. Furthermore, we found
that the combination of the risk alleles demonstrated
a more robust association with the modiﬁed Gensini
scores than any single 1 after adjustment for the
traditional clinical risk factors. Importantly, we
conﬁrm that the rs2266788 C allele destroys the
miR-3201 binding site at APOA5 30- UTR, which
damages the binding ability of miR-3201 and results
in the attenuated degradation of APOA5 mRNA
induced by normal miRNA-3201 binding and then
increases its translation and plasma APOA5 level.
Additionally, a dose response between the number
of inherited copies of the risk allele rs2266788 and
CAD severity was markedly illuminated, and the
functional study partly supports this effect. These
ﬁndings could have signiﬁcant clinical implications
on evaluating the degree of coronary artery stenosis
or the possibility of revascularization strategies in
patients with multivessel CAD.
The current ﬁndings support previous results that
showed that severe HTG subjects were carriers
of rare heterozygous loss-of-function mutations in
candidate lipoprotein metabolism genes (22,23).
Among these polymorphisms, our study was the ﬁrst
to provide reliable evidence of an association be-
tween rs2266788 and the triglyceride level in the
Chinese Han population. This SNP located at 158-bp
TABLE 4 Analysis of Coronary Artery Disease Patients With the Diagnosis Determined by Angiography
Cohort
Gene
Dosage
rs2266788
pdominant*
Adjusted OR
(95% CI)
rs662799
pdominant*
Adjusted OR
(95% CI)TT TC CC TT TC CC
Early onset
(n ¼ 917)
0VD 59 (10.7) 34 (10.6) 0 (0) 47 (10.0) 45 (11.4) 1 (1.9)
1VD 178 (32.4) 100 (31.2) 11 (23.9) 154 (32.8) 114 (28.7) 7 (13.5)
2VD 144 (26.2) 95 (29.6) 13 (28.3) 125 (26.7) 104 (26.3) 21 (40.4)
2VD+1VD+0VD 381 (69.3) 229 (71.4) 24 (52.2) TT+TC vs. CC (ref.) 326 (69.5) 263 (66.4) 29 (55.8) TT+TC vs. CC (ref.)
3VD 169 (30.7) 92 (28.6) 22 (47.8) 0.01 1.89 (1.18–2.78) 143 (30.5) 133 (33.6) 23 (44.2) 0.066 1.69 (0.96–2.88)
Late onset
n ¼ 1,149
0VD 53 (8.2) 50 (11.4) 4 (6.1) 43 (7.7) 49 (9.6) 5 (7.3)
1VD 163 (25.2) 124 (28.4) 12 (18.2) 148 (26.5) 133 (26.0) 15 (21.7)
2VD 211 (32.7) 115 (26.3) 18 (27.3) 179 (32.1) 133 (26.0) 19 (27.5)
2VD+1VD+0VD 427 (66.1) 289 (66.1) 34 (51.6) TT+TC vs. CC (ref.) 370 (66.3) 315 (61.6) 39 (56.5) TT+TC vs. CC (ref.)
3VD 219 (33.9) 148 (33.9) 32 (48.4) 0.02 1.83 (1.11–2.78) 188 (33.7) 196 (38.4) 30 (43.5) 0.21 1.37 (0.84–2.25)
Combined
(n ¼ 2,066)
0VD 112 (9.4) 84 (11.1) 4 (3.6) 100 (9.6) 94 (10.4) 6 (4.9)
1VD 341 (28.5) 223 (29.4) 25 (22.3) 302 (29.1) 247 (27.2) 22 (18.2)
2VD 355 (29.7) 211 (27.8) 29 (25.9) 304 (29.4) 237 (26.1) 40 (33.1)
2VD+1VD+0VD 808 (67.6) 518 (69.3) 58 (51.8) TT+TC vs. CC (ref.) 706 (68.1) 578 (63.7) 68 (56.2) TT+TC vs. CC (ref.)
3VD 388 (32.4) 240 (31.7) 54 (48.2) 8.96  104 1.96 (1.31–2.14) 331 (31.9) 330 (36.3) 53 (43.8) 0.06 1.41 (0.98-1.89)
Values are n (%) of subjects successfully genotype. *pdominant value and OR and 95% CI were adjusted for sex, age, hypertension, diabetes, lipids, and body mass index in patients with early- or late-onset
coronary artery disease and combined analysis.
CI ¼ conﬁdence interval; OR ¼ odds ratio; 1VD ¼ 1-vessel disease; 2VD ¼ 2-vessel disease; 3VD ¼ 3-vessel disease.
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273downstream of the APOA5 gene was reported to be
closely associated with familial combined hyperlip-
idemia in Hong Kong Chinese (24,25). Another
2 SNPs, rs662799 and rs964184, which were pre-
viously reported to be signiﬁcantly associated with70
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(A) The rs2266788 T/C variant occurs at the miR-3201-binding site. The variant rs2266788 is a T-to-C change (mRNA sequence as reference)
located at the predicted binding site for miR-3201 in the 30 UTR of the APOA5 gene. At the rs2266788, allele T base-paired with U in the
Watson-Crick mode (solid line), whereas allele C did not (shown without line). Testing the interaction between miR-3201 and APOA5 using a
reporter gene assay in 293T cells (B) and HepG2 cells (C). Luciferase assays showing allele-speciﬁc targeting of the miR-3201 to APOA5 in 293T
cells and HepG2 cells. pMIR-T or pMIR-C luciferase plasmid was cotransfected with negative control mRNA (miR-NC) or miR-3201. At least
6 replicate assays were performed for each transfection. (D) miR-3201 negatively regulates APOA5 through binding to 30 UTR of the APOA5.
Inhibiting the expression of hsa-miR-3201 increased APOA5 expression in HepG2 cells analyzed by Western blotting. (E) Rescue of miR-3201
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glyceraldehyde 3-phosphate dehydrogenase. Continued on the next page.
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274observed in the Chinese Han population (r2 ¼ 0.92,
1000 Genomes Pilot 1 Project). Thus, this may pro-
vide an explanation that the GWAS-sensitive site
rs662799 could well capture rs2266788. Indeed, a
recent GWAS from a Chinese Han male cohort
conﬁrmed a strong association between serum tri-
glyceride levels and rs651821 (27), which was in a
high LD (r2 ¼ 0.917) with rs662799 and (r2 ¼ 1.0) with
rs2266788 (1000 Genomes Pilot 1 Project) in the
Chinese Han population.
We also found some evidence of a combined effect
in common risk alleles. There was a strong association
between the triglyceride level and increasing gene
dosage of the risk scores. This discovery indicates
that the functional properties of multiple variantsmay act together to inﬂuence the development of an
atherosclerotic lesion.
Genetic variants in the APOA5/A4/C3/A1 gene
cluster have been consistently associated with CAD
risk. In the current study, we identiﬁed that a gene
dosage of 2 SNPs (rs662799 and rs2266788) was
signiﬁcantly related to the modiﬁed Gensini scores.
The SNP rs662799, a regulatory variant in promoter
(-1131T>C) of APOA5, have been shown to be related
to the risk of coronary heart disease in an analogous
dose-dependent manner, with w18% higher risk per
C allele (13). A recent study also reported the ge-
notype combinations of common variants including
rs662799 causally associated with myocardial
infarction with a corresponding odds ratio of 1.87
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275(95% conﬁdence interval: 1.25 to 2.81) (28). Our
data are consistent with this observation and imply
that the rs662799 gene dosage response for CAD
severity was evident, even among patients under-
going their ﬁrst catheterization. Our study also dem-
onstrates a signiﬁcant relationship with modiﬁed
Gensini scores. However, functional assays of this SNP
individually could not provide any explanation for
this association (20), and Palmen et al. (20) indicated
this allele may act in a cooperative manner (i.e., these
SNPs may act cooperatively or there is interaction
between them) (21). The variant rs2266788 also func-
tions as a predictor of the disease severity. This effect
was evident not only in right coronary artery stenosis
but also in complex manifestations of CAD. This
ﬁnding raises the possibility that patients with a
homozygous risk genotype may experience a greater
atheromatous burden in the asymptomatic phase
of the disease. Thus, screening for rs2266788 maycapture an anatomically relevant disease before
symptoms.
rs662799 does not functionally affect the rela-
tive luciferase expression or transcription factors
mapped to this site. On the contrary, the rs2266788 C
allele damages the miR-3201 binding site at APOA5–30
UTR and subsequently decreases APOA5 degradation,
while elevating circulating APOA5 levels. We used
the HLF cells with heterozygous genotype (rs2266788
CT) to conduct experiments and conﬁrm the effects
of miR-3201 on the binding site at APOA5–30 UTR
and APOA5 expression. Given previous knowledge
about SNP rs2266788 function and the high LD be-
tween rs2266788 and rs662799, we hypothesize that
rs2266788, not rs662799, is the causal variant. How-
ever, the function of miR-3201 is largely unknown,
although it has been reported to be expressed and
upregulated in melanoma (29). It should be noted
that the expression level of miR-3201 is higher in
CENTRAL ILLUSTRATION Role of miR-3201 in the Regulation of APOA5 Transcription
The variant rs2266788 is a T-to-C change (messenger RNA [mRNA] sequence as reference) located in the predicted binding site for microRNA
3201 (miR-3201) in the 30 UTR of the APOA5 gene. miR-3201 is processed in hepatocytes and binds to the 30 UTR of the APOA5 gene. The
rs2266788 C allele destroys the miR-3201 binding site at APOA5 30 UTR, which damages the binding ability of miR-3201 and results in the
reduced degradation of APOA5 mRNA and subsequently increases its translation and increases the plasma APOA5 level, which enhances
atherosclerosis and the development of coronary artery disease. SNP ¼ single nucleotide polymorphism.
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276HepG2 cells than in 293T cells (Online Fig. 7), which
may partly explain the difference in the luciferase
expression level for allele-speciﬁc constructs in
different cells.
STUDY L IM I TA T I ONS . There are several limita-
tions of our study that must be acknowledged.
The ﬁrst limitations of our ﬁne-mapping study
design are that we were underpowered to detect
associations with SNPs at MAF <0.05, and we
limited sequencing to regions most likely to harbor
functional variation. Second, the subjects recruited
in our study may not be entirely representative of
the general Han Chinese population; the potential
false-positive results are still possible even after
multiple corrections. It is important to conﬁrm these
positive association in prospective cohort studies.
Third, we tried to ﬁnd a mouse or rat model to
validate the effect of miR-3201 in vivo. Unfor-
tunately, a suitable animal model match was not
available, which is a limitation of our study. Finally,
the mechanism by which motif binding to miR-3201
could regulate the plasma levels of APOA5 is not
fully understood and requires further elucidation in
the future.CONCLUSIONS
Our results suggest that a complex genetic architec-
ture of both common and rare variants in a spectrum
of triglyceride-associated genes is responsible for
HTG. Our ﬁndings also showed that the gene dosage
of the APOA5/A4/C3/A1 gene cluster risk allele pre-
dicts CAD burden. Furthermore, the rs2266788 C
allele destroys the miR-3201 binding site at APOA5 30
UTR, therefore increases translation of APOA5 and
subsequently increases the plasma APOA5 level.
ACKNOWLEDGMENT S The authors thank Drs.
Xunna Bao, Kun Miao, Jia Peng, and Luo Zhang for
their efforts in recruiting patients and controls for
this study. They especially acknowledge all the
participants in this study.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
DaoWenWang or Dr. Hu Ding, Departments of Internal
Medicine and Institute of Hypertension, Tongji Hos-
pital, Tongji Medical College, Huazhong University of
Science and Technology, 1095# Jiefang Avenue,
Wuhan 430030, People’s Republic of China. E-mail:
dwwang@tjh.tjmu.edu.cn or huding@tjh.tjmu.edu.cn.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Genome-
wide association studies have identiﬁed APOA5/A4/C3/A1
gene cluster polymorphisms associated with hypertrigly-
ceridemia and an increased risk of CAD.
TRANSLATIONAL OUTLOOK: Prospective studies are
needed to assess the clinical utility of genotyping for
APOA5/A4/C3/A1 polymorphisms and the efﬁcacy of
therapeutic interventions, including those that specif-
ically target serum triglycerides to reduce the risk of
ischemic events.
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